Editor’s note: In this stock market, there are many opportunities to make significant money not based on fundamentals but with short term trades based on the known behavior of the momo crowd. Investors should consider taking advantage of such opportunities in addition to long term investments.
The Arora Report provides many such opportunities in addition to the very long term Core Model Portfolio.
This post was just published in ZYX Buy Change Alert.
A NEW IDEA ON COVID VACCINE COMPANY OCGN
Ocugen (OCGN) has a license from an Indian vaccine maker to get the approval of the vaccine in the U. S. The stock closed at $9.31. The stock has fallen $3.65 to $5.65 as of this writing the premarket. The news is that OCGN will seek full approval instead of emergency use authorization.
On a fundamental basis, the stock is worth a lot less than where it is trading.
As full disclosure, a prior short signal from ZYX Short is being pasted below.
The reason for buying is that the momo crowd is likely to run it back up. This is suitable only for aggressive investors.
The stock is very volatile. The buy zone is $5.02 to $6.51, preferably below $5.75. The stop zone is $4.23 to $4.38. Those desiring a closer stop can use $4.83 to $4.88. The first target zone is $7.73 to $8.31. The second target zone is $9.23 to $11.37. The maximum quantity is 25% of full core position size.
SIGNAL LIMITED: A NEW IDEA ON INDIAN VACCINE MAKER PARTNER IN THE U. S. OCGN
Signal Limited is a Signal(s) with a great record in similar situations but does not meet all of the stringent criteria for a Signal. Typically Signal Limited has higher risk-reward compared to a Signal over the short term.
OCGN has a license to seek approval and sell a vaccine from India in the United States. In our analysis, this is simply a pipe dream of the momo crowd. Given the effectiveness and abundance of PFE and MRNA vaccines in the United States, in our analysis, the stock is worth less than $2. OCGN is trading at $10.28 as of this writing in the aftermarket but traded as high as $13.75 today. Although OCGN is not directly affected by the Biden administration’s decision to grant patent waivers for vaccines, the waivers will put pressure on all vaccine stocks.
The call to short sell is based on the proposition that smart money will short sell this stock. If smart money does not short sell this stock, the trade will lose money as the momo crowd will pump it back to the $13 to $17 range. For this reason, it is suitable only for aggressive investors able to handle a wide range.
The short zone is $10 to $12.47. The maximum recommended quantity is 25% of full core position size. More later so the post can get to you quickly.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
